EHA 2024 | Long-term outcomes of chemo-free regimens in APL: real-world data and the TUD-APOLLO-064 trial
Maria Teresa Voso
• 14 Jun 2024
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, discusses long-term outcomes in the chemo-free era for acute promyelocytic leukemia (APL). Real-world data from the HARMONY database demonstrate a substantial survival advantage with the arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) regimen, with a median follow-up of 5.5 years. The TUD-APOLLO-064 trial (NCT02688140) further confirms favorable outcomes for patients treated with this regimen. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
